Welcome to Equine herpes virus vaccine!

The virus even when will prevent infection from active widely from being completely asymptomatic throughout a person's life.

22.06.2014

Current news on genital herpes vaccines, natural medicine for prostate cancer - Try Out

Author: admin
Agenus Inc said a trial of its experimental genital herpes vaccine reduced the rate at which patients released the virus, reducing the likelihood of infecting others, sending its shares up 32 percent in premarket trading. The 15 percent reduction in the release of the virus by patients receiving the vaccine in a mid-stage trial compared to those on a placebo, who showed no reduction.
The mid-stage trial had 80 patients with a history of 1-9 herpes recurrences within the prior 12 months. The trial tested the efficacy of the vaccine by measuring the release of the virus by patients 45 days before and after three injections of HerpV.
Genital herpes, a highly contagious sexually transmitted infection, is usually caused by the herpes simplex virus (HSV).
The company's partners are also testing the QS-21 Stimulon adjuvant in combination with other vaccines. Initial, positive results have been reported for a therapeutic vaccine candidate for treating patients with genital herpes.


Wald and her team presented the initial findings of the first-in-human clinical trial of the novel GEN-003 T cell vaccine Sept.
The vaccine contains, among other components, a proprietary adjuvant, trademarked Matrix-M.
A majority of the patients also received a booster injection, given 6 months after the first vaccination. There are two types of HSV and Agenus's vaccine targets HSV type 2, which most often causes genital herpes. Centers for Disease Control and Prevention, 776,000 people in the United States get new herpes infections annually and one out of six people aged 14 to 49 years has genital HSV-2 infection. This first-in-class, investigational, protein subunit vaccine, GEN-003, is under development by Genocea Biosciences Inc.
T cell vaccine research is trying to find safe, effective ways to spur this protective reaction.


However, an exploratory analysis suggested that the interval between the first immunization with GEN-003 and the next recurrence of genital herpes might be longer in those receiving the actual candidate vaccine, rather than the placebo injection. Wald is enrolling women infected with herpes simplex virus 2 in a study to see whether the drug tenofovir, given orally or as a vaginal gel, reduces genital shedding of the virus. Genocea, located near Boston, is a clinical-stage biopharmaceutical company for the discovery and development of T cell vaccines to prevent and treat infectious diseases.




What to take for herpes outbreak
Alternative medicine for adhd in adults
How do you treat hpv virus


Comments to “Current news on genital herpes vaccines”

  1. Ramin62:
    Have never had one again in the life, and I will.
  2. Devushka_Jagoza:
    The herpes zoster treatment precautionary while.